• The collaboration aims to enhance the development and deployment of integrated quantum and generative AI solutions within D-Wave’s Leap™ quantum cloud platform
• The partnership’s development efforts will target more efficient and energy-saving model training, higher-performing models, and the combined application of Generative AI and quantum optimization
• The commercial expansion includes a one-year enterprise subscription to Orquestra®, Zapata AI’s powerful software development and collaboration platform designed for creating and deploying Universal Generative AI applications at scale
• D-Wave recently hosted British Columbia (B.C.) Minister of State for Trade, Jagrup Brar, and B.C. Parliamentary Secretary for Labour, Janet Routledge, at its Burnaby-based Quantum Engineering Center of Excellence

D-Wave Quantum (NYSE: QBTS), a pioneer in quantum computing systems, software, and services, and Zapata Computing Holdings (NASDAQ: ZPTA), known for its expertise in industrial generative AI software solutions, have announced a notable expansion of their commercial partnership. The collaboration aims to accelerate the development and deployment of integrated quantum and generative AI solutions in D-Wave’s Leap quantum cloud platform (https://ibn.fm/jcUJp).

The expanded agreement will utilize Zapata’s proprietary universal generative AI software for rapid development and build on D-Wave’s Leap real-time quantum cloud service to support quantum, hybrid quantum, and classical AI solutions. The partnership’s development efforts will target more efficient and energy-saving model training, higher-performing models, and the combined use of generative AI and quantum optimization.

The broadened collaboration is taking place at a time when quantum computing is showing its potential to enhance the accuracy and efficiency of AI model training. By utilizing AI’s predictive capabilities, quantum computing can optimize business processes more effectively. This technology has the potential to enhance AI for specific enterprise applications, promoting sustainability, reducing costs, and improving operational efficiency. Quantum computing could advance AI development for complex, large-scale computational models, deep learning, natural language processing, and computer vision, all while minimizing energy consumption.

Dr. Alan Baratz, CEO of D-Wave, said the strategic relationship with Zapata AI brings the company a step closer to delivering the transformative combined power of universal generative AI and quantum computing in a single cloud platform. “Zapata AI has been pioneering quantum-based generative modeling for over five years, well before generative AI stole headlines and became a mainstream enterprise priority,” Baratz said. “We are excited to deepen our partnership with Zapata and leverage their industry-leading algorithmic capabilities and scientific expertise to bring a quantum-enabled generative AI platform to market.”

D-Wave also recently hosted B.C. Minister of State for Trade, Jagrup Brar, and B.C. Parliamentary Secretary for Labour, Janet Routledge, at its Burnaby-based Quantum Engineering Center of Excellence. The officials toured the facility to gain insights into D-Wave’s advancements in quantum computing and its global efforts to promote quantum adoption (https://ibn.fm/DRo9N).

During the visit, D-Wave and the Quantum Algorithm Institute (“QAI”) announced an expanded training program to provide Canadian students and researchers with access to the Leap quantum cloud service in an effort to develop a quantum-ready workforce. This program has seen solid traction, with nearly 5000 problems submitted by students so far.

D-Wave shared key company advancements with the government officials, including its new hybrid quantum solver, enhanced qubit architecture, and real-world applications that address e-commerce, sustainability, and public sector challenges. The officials acknowledged D-Wave’s role in driving innovation, creating jobs, and its commitment to workforce development through its partnership with QAI.

For more information, visit the company’s website at www.DWaveQuantum.com.

NOTE TO INVESTORS: The latest news and updates relating to QBTS are available in the company’s newsroom at https://ibn.fm/QBTS

Forward-Looking Statements

Certain statements in this press release are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management’s control, including the risks set forth under the heading “Risk Factors” discussed under the caption “Item 1A. Risk Factors” in Part I of the company’s most recent Annual Report on Form 10-K or any updates discussed under the caption “Item 1A. Risk Factors” in Part II of the company’s Quarterly Reports on Form 10-Q and in the company’s other filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this press release in making an investment decision, which are based on information available to the company on the date hereof. The company undertakes no duty to update this information unless required by law.

The FinovateFall 2024 event, held from September 9-11, 2024, at the Marriott Marquis Times Square, New York, offers the premiere interactive business platform, for industry experts, startups, and unicorns, to stage demos and showcase innovative ideas.

FinovateFall New York will witness 2,000+ attendees interacting with peers and industry leaders on the event floor, with over 1,000 bank and financial institution representatives, and with 1,400+ attendees being top executives, directors, and VPs. Directly connected to the exhibition floor, the event features 60+ demos from companies aspiring for business opportunities.

The agenda of the FinovateFall includes general sessions, demos, exhibit hall networking, keynote addresses, and executive briefings on pivotal topics regarding financial services and technology. Drinks and dinner breaks offer attendees a great opportunity to connect directly with industry stalwarts and develop strong networking ties. The agenda is designed for attendees to gain expert insights and help them smoothly navigate their financial and fintech businesses in the future.

The event will feature an out-of-the-box keynote address by Ken Hughes, A Consumer Behaviouralist and King of Customer Experience, in the Session: The Blue Dot Consumer. Around 120 eminent industry dignitaries will preside over the keynote speaker sessions. These industry leaders will share their expertise and discuss the latest topics, including AI and wealth management, regulatory services, competing in the digital world, and third-party risk management, to name a few.

Investors can discover fresh ideas and new investment avenues among these demos and exhibits. There will be over countless meetings where investors can meet companies and entrepreneurs on a one-to-one basis. Fintech companies with sustainability and inclusion ideas can also avail the Fintech scholarship program.

To know more, please visit https://ibn.fm/5x9bn

• The report explores the growth, competition, and consumer trends, for lesser known cannabinoids
• The report highlights a 5.4% revenue increase in the edible market for 2023, with total sales reaching $2.097 billion
• As consumer preferences shift towards edibles for their therapeutic effects and consistent experiences, the industry product landscape is set to evolve

With the increasing acceptance of cannabis use in society, the popularity of edibles—products containing cannabinoids that can be consumed as food or drink—has surged. While many consumers are familiar with edibles containing THC (tetrahydrocannabinol), known for its euphoric effects, or CBD (cannabidiol), recognized for its therapeutic benefits, there is a growing interest in edibles infused with non-intoxicating minor cannabinoids. These lesser-known cannabinoids offer unique properties and potential health benefits, driving significant market growth.

BayMedica, a subsidiary of InMed Pharmaceuticals (NASDAQ: INM), specializes in rare cannabinoids, and has published a report on the expansion of the minor cannabinoid market in 2023. Link to a full copy of the report can be found at https://ibn.fm/Jowk5.

The report, based on data from Headset, the largest industry dataset, explores the growth, competition, and consumer trends in ten regulated states, encompassing 85 million of the 158 million residents in areas where recreational cannabis is legal (https://ibn.fm/74fQB).

The report highlights a 5.4% revenue increase in the edible market for 2023, with total sales reaching $2.097 billion. This growth is attributed to innovative developments in minor cannabinoid products. Among edible products, gummies demonstrated robust sales, while minor cannabinoid-infused edibles experienced an impressive 47% year-over-year growth, totaling $391 million in sales.

Despite a decrease in the average price of edible items from $14.29 to $12.54, the strong consumer demand and reduced production costs have made minor cannabinoids a strategic focus for brands aiming to secure a competitive position in the industry.

Minor cannabinoids, although less prominent than THC and CBD, are gaining attention for their distinctive properties and potential health benefits. These compounds, found in smaller quantities in cannabis plants, are transforming the cannabinoid landscape. Key minor cannabinoids include:

• Cannabichromene (“CBC”): Known for enhancing the body’s natural endocannabinoid, anandamide, by prolonging its presence in the bloodstream
• Tetrahydrocannabivarin (“THCV”): Non-psychoactive, it may suppress appetite and enhance focus and energy
• Cannabidivarin (“CBDV”): Similar to CBD, it potentially supports brain, immune, and gut health
• Cannabinol (“CBN”): Mildly psychoactive, known for its sedative and antibacterial properties, beneficial for insomnia and pain relief

The endocannabinoid system (“ECS”), discovered in the late 1980s, plays a crucial role in regulating various body functions. Every cell type has cannabinoid receptors that interact with over 140 known cannabinoids. The ECS’s therapeutic potential spans numerous diseases, though extracting minor cannabinoids is challenging due to their low quantities and the high cost of separation. BayMedica’s advancements in biosynthesis and synthetic chemistry now allow for commercial-scale production, opening new therapeutic avenues.

In 2023, nearly half of the top 50 selling edibles contained minor cannabinoids, reflecting a significant market trend. Leading brands are innovating with formulations that appeal to a diverse consumer base, allowing them to command premium pricing for minor cannabinoid products. These products have a 6.3% higher average price and a 73% higher average EQ (Equivalent) price compared to THC-only products, indicating a strong consumer willingness to pay for added benefits. The entourage effect theory suggests that combining minor cannabinoids with major cannabinoids like THC and CBD enhances medicinal benefits, such as pain relief.

Commercial adoption of minor cannabinoids in edibles provides insights into consumer preferences. CBN has emerged as a leader in sales, likely due to its sedative effects. CBG, while currently strong, may see a future decline as other minor cannabinoids gain traction. CBC and THCV have shown significant sales growth in 2023, driven by research into their potential benefits and increased production efficiency.

As consumer preferences shift towards edibles for their therapeutic effects and consistent experiences, the cannabis product landscape is set to evolve. Brands must align with these changing needs, emphasizing minor cannabinoids for holistic well-being. BayMedica remains committed to scaling operations and expanding product offerings to meet the rising demand for high-quality cannabinoids, supporting a broad and growing customer base.

For more information, visit the company’s website at www.InMedPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at https://ibn.fm/INM

• Clene is developing a new class of drugs that hold the potential to transform the lives of millions suffering from debilitating conditions such as Amyotrophic Lateral Sclerosis (“ALS”), Multiple Sclerosis (“MS”), and Parkinson’s Disease (“PD”)
• CNM-Au8(R), Clene’s lead drug candidate, is a fundamentally new approach for treating the underlying factors contributing to ALS, MS, and PD, by restoring neuronal health and function
• ALS, the most prevalent adult-onset progressive motor neuron disease, affects approximately 30,000 people in the U.S.

Clene (NASDAQ: CLNN), a pioneering biopharmaceutical company, is making significant strides in the treatment of neurodegenerative diseases through its novel nanotherapeutic platform. With a mission to improve underlying mitochondrial health and protect neuronal function, Clene is developing a new class of drugs that hold the potential to transform the lives of millions suffering from debilitating conditions such as Amyotrophic Lateral Sclerosis (“ALS”), Multiple Sclerosis (“MS”), and Parkinson’s Disease (“PD”).

At the forefront of Clene’s innovations is CNM-Au8, a gold nanocrystal suspension currently in  development. CNM-Au8 is designed to act as a treatment for ALS, MS, and PD by restoring                neuronal health and function. The drug works by increasing cell energy production and utilization, driving critical cellular reactions that promote neuroprotection and remyelination, thereby enhancing neuronal and glial resilience to disease-related stressors.

In a recent Xtalks podcast, Clene discussed the significant developments of CNM-Au8 and its unique technology. CNM-Au8’s mechanism of action involves the conversion of critical energetic metabolites within living cells to produce ATP, the essential energy currency for cellular functions. The gold nanocrystals attract a coating of apolipoproteins from human plasma, facilitating their passage through the blood-brain barrier and into the brain, where they can protect neurons from death and repair damaged neurons by catalyzing energy production (https://ibn.fm/Gvb5o).

CNM-Au8 is being evaluated in multiple clinical trials, including the prestigious Harvard/MGH HEALEY ALS Platform Trial, which targets patients with mid-to-late stage ALS. The drug has also completed the RESCUE-ALS proof-of-concept clinical trial for early symptomatic ALS, and the REPAIR trials, showing promising changes in brain energy metabolites with CNM-Au8 administration. Additionally, CNM-Au8 has completed a clinical trial, VISIONARY-MS, for treating visual pathway deficits in chronic optic neuropathy, demonstrating its potential for remyelination in stable relapsing MS.

With more than 650 estimated years of collective exposure across ALS, MS, and PD participants in CNM-Au8 clinical trials and Expanded Access Protocol (compassionate use) programs, CNM-Au8 has shown a robust safety profile without any observed safety signals. The drug is designed to be used in combination with other agents and has no known drug-drug interactions, making it a versatile option for patients.

ALS, the most prevalent adult-onset progressive motor neuron disease, affects approximately 30,000 people in the U.S. and an estimated 500,000 people worldwide. Clene estimates that global ALS treatment sales will exceed $1 billion annually in the coming years, underscoring the urgent need for viable treatment options.

Founded in 2013 and based in Salt Lake City, Utah, Clene Inc. is at the forefront of developing innovative treatments for neurodegenerative diseases. With research and development, as well as manufacturing operations in Maryland, Clene is committed to transforming the treatment landscape for ALS, MS, PD, and other debilitating conditions through its groundbreaking nanotherapeutic platform.

For more information, visit the company’s website at www.Clene.com.

NOTE TO INVESTORS: The latest news and updates relating to CLNN are available in the company’s newsroom at https://ibn.fm/CLNN

• The U.S. snack market is predicted to grow to $169.6 billion by 2027
• 93% of adults regularly snack at night combining for over 1 billion bedtime snacks consumed every week.  Unfortunately, the most popular choices are both unhealthy and sleep-disruptive
• Nightfood, with their newly launched sleep-friendly cookie line, is poised to lead the burgeoning sleep-friendly nighttime snack category
• Earlier this month, Nightfood Holdings signed a letter of intent to acquire CarryoutSupplies.com, an established restaurant and foodservice packaging provider that is on the upswing after business suffered greatly during the pandemic

The U.S. snack market is experiencing robust growth, fueled by evolving consumer preferences that prioritize wellness and functionality.  According to Eurometer International, the U.S. snack market will reach $169.6 billion by 2027.  With never-ending social media and video streaming on demand, Americans are staying up later at night and snacking more than ever.

The late-night snacking occasion is a massive and untapped niche within the snack industry. A 2023 Sleep Foundation survey revealed that 93% of American adults snack between dinner and bed each week, with the average adult snacking before bed 3.9 nights per week. The result is over 1 billion nighttime snacks consumed by American adults every week, and a consumer spend estimated at well over $60 billion annually.

A recent survey by Kellanova (NYSE: K), formerly Kellogg Company, revealed that cookies, ice cream, and chips top the list of nighttime snacks. These are not only generally unhealthy, but their sugar, fat, and caloric content can also directly impair sleep quality. The immense consumer spend on snacks consumed before bed understandably has the attention of global snack giants such as Kellanova (NYSE: K), Nestle (OTC: NSRGY), Mondelez (NASDAQ: MDLZ), Post Holdings (NYSE: POST), and others.

Nightfood Holdings (OTCQB: NGTF) is pioneering the concept of sleep-friendly nighttime snacks and is largely alone in targeting an exploding consumer use case.  Nightfood is positioned to be the leader in the sleep-friendly nighttime snack category, which the brand is pioneering.  And now the company has made a move that signals new things to come which must not be overlooked.

In addition to its core sleep-friendly snack business, Nightfood has strategically focused on expanding its reach within the broader foodservice ecosystem. In July, the company announced a letter of intent to acquire CarryOutSupplies.com, a wholesale provider of packaging and supplies and to the foodservice industry. This move reflects NGTF’s ambition to become a comprehensive player in the sector.

Nightfood Holdings sees a golden opportunity in acquiring CarryOutSupplies.com right now. CarryOut is a well-established restaurant packaging distributor which has served a client base of over 7,000 foodservice and restaurant locations over the years.  The company is now bouncing back after COVID challenges.

CarryOut’s eco-friendly packaging solutions align perfectly with Nightfood’s focus on innovation and cater to a growing market trend. The reemerging company recorded sales of just over $2 million in calendar 2023, a positive sign, yet still a fraction of pre-COVID revenue. Nightfood believes CarryOut can not only regain pre-pandemic success but also surpass it, especially by targeting up and coming growth foodservice chains with CarryOut’s unique and eco-friendly packaging options.

A bolt-on of $2 million in sales certainly will look good in Nightfood’s books. The company launched robots-as-a-service (“RaaS”) model through its subsidiary, Future Hospitality Ventures Holdings, addressing labor cost and labor shortage in the hospitality industry.

As consumer preferences evolve and the demand for sleep-friendly options grows, Nightfood is well-positioned to capture a meaningful segment of the expanding late-night snacking market. By addressing the unmet needs of consumers with sleep-friendly snacks, Nightfood is not only shaping the future of the nighttime snacking category but also establishing itself as a major player in the broader landscape.

For more information, visit the company’s website at https://ir.nightfood.com/.

NOTE TO INVESTORS: The latest news and updates relating to NGTF are available in the company’s newsroom at http://ibn.fm/NGTF

Leaders of the pharma, biotech, and medical device healthcare industry, are invited to attend the 13th Advancing Women’s Leadership Skills & Opportunities In Pharma & Healthcare from September 23-25, 2024, in Philadelphia, PA.

This DGE program will focus on empowering women executives in leadership roles and closing the workplace gender gap. Success stories will be shared by women leaders who have succeeded after facing numerous career challenges. The event comprehensively offers insights into the life journeys of successful women, inspiring the attendees to overcome career hardships, achieve their goals, and seek the promotions they deserve.

The event is hosted by Dynamic Global Events (“DGE”), a Life Science leader in organizing b2b events. The global event company caters to the dynamic informational and networking needs of the Pharmaceutical, Biotechnology, Healthcare, Medical Devices, and allied industries.

Important “how to” topics to be covered:

• Strategies for Maneuvering the Landscape of the Board of Directors
• Break Through the Promotional Pipeline
• Cultivate Confidence – Tools to Improve Inner Belief and Executive Prescence
• Overcome Obstacles for Women’s Success: Generational Perspectives
• Maximize Opportunities to Shape Your Personal Brand
• Embracing Authentic Leadership and Passing It On to Teams
• Taking the High Road and Other Approaches for Getting Along at Work

The DGE conference includes keynote speaker sessions and discussion panels hosted by eminent industry leaders and women executives whose success journeys are an inspiration.

To know more, please visit https://ibn.fm/KMjev.

• Decentralized energy generation for specific geographic locations is growing in popularity as a solution for customers searching for climate-friendly alternatives
• Environmentally conscious corporations are likewise seeking solutions that will help them meet global sustainability goals and social and governance reporting
• Distributed energy solutions developer Correlate Energy Corp. is helping clients meet the challenges of the modern energy era, focusing on behind-the-meter solar infrastructure improvements, access to financing, and measurable progress in sustainable solutions
• Correlate Energy is using strategic partnerships to boost its ability to provide clients with data-driven responsiveness for decarbonization, site analysis, and design proposal needs

Companies worldwide are working to build environmental, social and governance (“ESG”) initiatives, while meeting the expectations of investors. A recent Deloitte survey indicates that a majority of US companies report progress on sustainability (https://ibn.fm/ZDILd).

At the same time, a recent Forbes column noted the difficulties that global corporations face in meeting deadlines and standards applied under a variety of agreements, ranging from the Corporate Sustainability Due Diligence Directive (“CSDDD”) in Europe to the Securities Exchange Commission’s (“SEC’s”) Climate Related Disclosure Standards in the U.S.

“The transition mandate in the CSDDD is a blessing in disguise for many firms because it will act as the impetus for a standard set of benchmarks for evaluating sustainability risk across supply chains and put some much-needed structure around data collection, reporting and actions,” the report states (https://ibn.fm/6E3ib). “That will, in turn, provide better insights for investors and consumers to evaluate each company’s real stance on sustainability on an apples-to-apples basis.”

Distributed energy solutions company Correlate Energy (OTCQB: CIPI) is making renewable energy measures more accessible for corporations and residential customers alike, increasing the incentive to make the transition to climate-friendly distributed energy systems.

As Correlate Energy develops its own localized clean energy solutions and microgrids, and helps clients figure out the best way to set up their own, it can connect them with sources of financing, manage the construction process, and ensure goals are being met while building reporting transparency in the process.

“Behind the meter solar … has been our focus for a long time, specifically on large commercial and industrial properties,” Correlate’s Solar Energy & Storage Director Jason Loyet said during a March webcast with analytics partner Xendee (https://ibn.fm/CbFKP). “I think a lot of developers and a lot of commercial sales people are getting approached by national portfolios — same with Correlate. We’re at a unique opportunity in the industry.”

Additionally, some utility clients are finding decentralized energy generation an attractive alternative to central grids beset by power outage problems insufficient infrastructure.

For more information, visit the company’s website at www.Correlate.Energy, including the following:

• Breaking Down Barriers To Your ESG Goals While Generating Additional Net Operating Income:  www.correlate.energy/our-process
• Platform Generates New Rent And Operating Income, Allowing You To Meet Your ESG Goals: www.correlate.energy/program

NOTE TO INVESTORS: The latest news and updates relating to CIPI are available in the company’s newsroom at https://ibn.fm/CIPI

• Fathom Nickel’s sprawling Gochager Lake Project covers 22,000+ hectares in the metal rich Trans-Hudson Corridor in Saskatchewan, Canada
• Located on the west side of the property about 10 kilometers from the Gochager deposit, the Mal Lake tenure hasn’t been explored since 1967; Fathom just re-evaluated available historic drill core
• The findings suggest similarities in nickel tenor, nickel-to-copper ratio, and even the source magma type between Mal Lake and Gochager Lake, hinting at a potential magmatic conduit system

Fathom Nickel (CSE: FNI) (FSE: 6Q5) (OTCQB: FNICF) is pointing towards a bright future for its Gochager Lake property, thanks to recent core reviews at the nearby Mal Lake nickel occurrence. A recent press release highlights the exciting potential of the newly acquired Mal Lake tenure and its possible connection to the Gochager Lake deposit, both of which are part of Fathom’s more than 22,000-hectare Gochager Lake project in the Trans-Hudson Corridor in Saskatchewan.

Mal Lake’s Hidden Potential

The Gochager Lake Project is host to a historic, NI 43-101 non-compliant open pit resource consisting of 4.3 million tons at 0.295% nickel (Ni) and 0.081% copper (Cu). Mal Lake nickel occurrence is located on the eastern portion of the project, about 10 kilometers from the historic deposit.

Mal Lake hasn’t been explored since 1967. However, the historic Mal Lake drill core is available through the Saskatchewan Ministry of Energy and Resources’ Precambrian Geological Laboratory in La Ronge, SK. Recently, Fathom took a closer look at the drill core. Re-evaluation revealed significant zones of nickel-copper-cobalt mineralization.

This data suggests similarities in nickel tenor, nickel-to-copper ratio, and even the source magma type between Mal Lake and Gochager Lake.

Exploration Plans: Investigate Similarities

The close proximity (10km) and geological similarities between Mal Lake and Gochager Lake suggest a potential link between the two. Fathom plans to drill Mal Lake during the next winter program, considering it a drill-ready target.

The jump to drilling is based on several key findings in the drill core:

• Portable X-ray Fluorescence (“pXRF”) analysis of the Mal Lake core revealed zones with high nickel (over 10,000 ppm), copper, and cobalt (over 1,000 ppm) mineralization. Importantly, cobalt wasn’t analyzed during the original 1967 drilling
• Nickel-to-sulfur (Ni/S), nickel-to-copper (Ni/Cu), and nickel-to-cobalt (Ni/Co) ratios from Mal Lake pXRF data closely resemble those from Gochager Lake assays
• This similarity in ratios suggests both areas may have originated from the same magma source, potentially forming part of a larger magmatic conduit system

The proximity of Mal Lake and Gochager Lake hints at the existence of additional mineralized intrusions within the vast Gochager Lake property. Fathom believes the 2008 VTEM data speaks to the possibility of a controlling structure hosting these intrusions.

Unlocking the Blue-Sky Potential

This discovery opens doors for exploring a much larger area with significant potential for additional nickel deposits. By analyzing geophysical data, Fathom aims to identify more intrusions along the same magmatic conduit system.

This paves the way for substantial resource expansion at Gochager Lake and the discovery of new mineralized zones. Overall, Fathom Nickel’s exploration efforts at Mal Lake are shedding light on the immense potential of the Gochager Lake property. The company’s data-driven approach and planned drilling activities position them well to unlock the blue-sky potential of this exciting region.

For more information, visit the company’s website at www.FathomNickel.com.

NOTE TO INVESTORS: The latest news and updates relating to FNICF are available in the company’s newsroom at https://ibn.fm/FNICF

Meta Platforms (NASDAQ: META), a leading technology company, has been making headlines with its significant advancements in artificial intelligence (“AI”). The company’s CEO, Mark Zuckerberg, recently announced that Meta’s AI assistant is on track to become the most utilized in the world. This statement underscores the company’s commitment to AI technology and its potential to drive future growth. Meta, known for its social media platforms like Facebook and Instagram, is now positioning itself as a key player in the AI space, competing with other tech giants.

The recent performance of META’s stock reflects the dynamic nature of the tech industry. Despite the promising developments in AI, the company’s stock price experienced a decrease of 1.16% to $491.98. This change indicates the market’s immediate reaction to various factors, including the company’s strategic investments and the broader economic environment. The stock’s movement, with a low of $476.15 and a high of $501.15 during the trading session, showcases the volatility and investor sentiment surrounding tech stocks.

Over the past year, META’s stock has seen a wide range of prices, from a low of $274.38 to a high of $542.81. This fluctuation highlights the challenges and opportunities the company faces in a competitive and rapidly changing market. With a market capitalization of approximately $1.25 trillion, Meta Platforms remains a heavyweight in the tech industry, demonstrating the scale of its operations and its significant impact on the market.

The trading volume of 12.75 million shares further illustrates the active interest in META’s stock among investors. This level of activity is indicative of the market’s keen eye on Meta’s strategic moves, especially its investment in AI technology. As the company continues to develop its AI assistant and other innovative technologies, investors and the market at large will closely watch Meta’s performance for signs of long-term growth and profitability.

In summary, Meta Platforms’ focus on artificial intelligence is a strategic move that has the potential to redefine its role in the tech industry. Despite the recent dip in stock price, the company’s significant market capitalization and active trading volume reflect its enduring influence and the high stakes of its AI ambitions. As Meta continues to innovate, its journey offers valuable insights into the intersection of technology, investment, and market dynamics.

For more information, visit the company’s website at https://investor.FB.com.

The 4th Chief Patient Officer Summit held on July 15-16, 2024, was a resounding success, bringing together industry leaders, experts, and stakeholders to discuss and shape the future of patient-centric healthcare. The event featured insightful sessions, interactive panel discussions, and valuable networking opportunities, all aimed at enhancing patient engagement and care. 

Highlights from the Summit

Keynote Sessions: 

• Kay Matthews shared a “Trail Blazer Keynote: Knowledge Builds Community Trust”
• Beth Frates, MD, delivered an insightful keynote on “Restore – Recharge – Renew: PAVING the Path to Wellness: Thriving with a Healthy Body, Peaceful Mind and Joyful Heart
• Rene Russo, Pharm.D., presented an empowering Leadership Keynote Fireside Chat

Interactive Panels and Discussions: 

• Amplify Patient Voice in Market Access 
• Decode the Regulatory Pathway and Community Influence in Regulatory Decision-Making
• Elevate Equity from Inception and Sustain Inclusion through Post Marketing 
• Operationalize Patient-Inclusivity: Anticipate, Minimize, and Exit the “Sticky Middle” 
• Drive Community Health Equity by Uniting National and Local Collaborations 
• Patient Assistance: What You Should Know As A Patient Advocate 
• Gain Techniques for Successful Measurement and Reporting 
• Examine Publishing Trends with Partners
• Red Cell Revolution Reveals Authentic Patient Engagement

On-Demand Access Now Available 

For those who couldn’t attend or want to revisit the valuable content, we are pleased to announce that on-demand access is now available. Attendees can register to watch the entire summit from anywhere, at any time. This flexible option ensures that you don’t miss out on the wealth of knowledge and insights shared during the event. Register for on-demand access.

Looking Ahead 

We extend our gratitude to all speakers, sponsors, and participants for making the Chief Patient Officer Summit a memorable and impactful event. As we continue to champion patient-centered healthcare, save the date for Chief Patient Officer Summit West on January 29-30, 2025, in San Diego, CA.

Learn more information and register for upcoming events with Dynamic Global Events.